Melatonin and radioprotection from genetic damage: In vivo/in vitro studies with human volunteers

Mutation Research - Genetic Toxicology

Volumn 371, Issue 3-4, 1996, Pages 221-228

  Vijayalaxmi, ^a   Reiter, Russel J ^a   Herman, Terence S ^a   Meltz, Martin L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Chromosome aberrations; Gamma radiation; Melatonin; Micronuclei; Radioprotection

Indexed keywords

MELATONIN;

ADULT; ARTICLE; CHROMOSOME ABERRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENETIC DAMAGE; HUMAN; HUMAN EXPERIMENT; LYMPHOCYTE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIATION MUTAGENESIS; RADIATION PROTECTION; VOLUNTEER;

EID: 0030596153     PISSN: 01651218     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1218(96)90110-X     Document Type: Article

References (29)

1. Waldhauer F., Dietzel M. Daily and annual rhythms in human melatonin secretion: Role in puberty control. Ann. NY Acad. Sci. 453:1985;205-214.
2. Reiter R.J. Melatonin: The chemical expression of darkness. Mol. Cell. Endocrinol. 79:1991;c153-c159.
3. Reiter R.J. The pineal gland and its hormones in the control of reproduction in mammals. Endocrine Rev. 1:1980;109-131.
4. Reiter R.J. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocrine Rev. 12:1991;151-180.
5. Reiter R.J. The ageing pineal gland and its physiological consequences. BioEssays. 14:1992;169-175.
6. Reppert S.M., Weaver D.R., Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian rhythms. Neuron. 13:1994;1177-1185.
7. Carlberg C., Wiesenberg I. The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase: an unexpected relationships. J. Pineal Res. 18:1995;171-178.
8. Tan D.-X., Chen L.-D., Poeggeler B., Manchester L.C., Reiter R.J. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr. J. 1:1993;57-60.
9. Tan D.-X., Poeggeler B., Reiter R.J., Chen L.-D., Chen S., Manchester L.C., Barlow-Walden L.R. The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett. 70:1993;65-71.
10. Tan D.-X., Reiter R.J., Chen L.-D., Poeggeler B., Manchester L.C., Barlow-Walden L.R. Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the carcinogen safrole. Carcinogenesis. 15:1994;215-218.
11. Blickenstaff R.T., Brandstadler S.M., Reddy S., Witt R. Potential radioprotective agents. 1. Homologs of melatonin. J. Pharm. Sci. 83:1994;216-218.
12. Vijayalaxmi, Reiter R.J., Metlz M.L. Melatonin protects human blood lymphocytes from radiation-induced chromosomes damage. Mutation Res. 346:1995;23-31.
13. Vijayalaxmi, Reiter R.J., Sewerynek E., Poeggeler B., Leal B.Z., Meltz M.L. Marked reduction of radiation-induced micronuclei in human blood lymphocytes pre-treated with melatonin. Radiat. Res. 143:1995;102-106.
14. Roots R., Okada S. Protection of DNA molecules of cultured mammalian cells from radiation-induced single-strand scissions by various alcohols and SH compounds. Int. J. Radiat. Biol. 21:1972;329-342.
15. Okada S., Nakamura N., Sasaki K. Radioprotection of intracellular genetic material. Nygaard O.F., Simic M.G. Radioprotectors and Anticarcinogens. 1983;339-356 Academic Press, New York.
16. Littlefield L.G., Joiner E.E., Colyer S.P., Sayer A.M., Frome E.L. Modulation of radiation-induced chromosome aberrations by DMSO, an OH radical scavenger. 1: Dose-response studies in human lymphocytes exposed to 220 kV X-rays. Int. J. Radiat. Biol. 53:1988;875-890.
17. Fraser S., Cowen P., Franklin M., Franey C., Arendt J. Direct radioimmonuassay for melatonin in plasma. Clin. Chem. 29:1983;369-397.
18. Perry P., Wolff S. New Giemsa method for the differential staining of sister chromatids. Nature (Lond.). 251:1974;156-158.
19. Vijayalaxmi, Burkart W. Resistance and cross-resistance to chromosome damage in human blood lymphocytes adapted to bleomycin. Mutation Res. 211:1989;1-5.
20. Lieberman H.R., Waldhauser F., Garfield G., Lynch H.J., Wurtman R.J. Effects of melatonin on mood and performance. Brain Res. 323:1984;201-207.
21. Voordouw B.C., Euser R., Verdonk R.E., Alberda B.T., de Jong F.H., Drogendijk A.C., Fauser B.C., Cohen M. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function and can inhibit ovulation. J. Clin. Endocrinol. Metab. 74:1992;108-117.
22. Dollins A.B., Zhdanova I.V., Wurtman R.J., Lynch H.J., Deng M.H. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc. Natl. Acad. Sci. USA. 91:1994;1824-1828.
23. Menendez-Pelaez A., Reiter R.J. Distribution of melatonin in mammalian tissues: the relative importance of nuclear versus cytosolic localization. J. Pineal Res. 15:1993;59-69.
24. Arendt M., Aldhous M., Marks V. Alleviation of jet lag by melatonin: priliminary results of controlled double blind trial. Br. Med. J. Clin. Res. Ed. 292:1986;1170.
25. Lissoni P., Barni S., Crispino S., Tancini G., Fraschini F. Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur. J. Cancer Clin. Oncol. 25:1989;789-795.
26. Lissoni P., Barni S., Rovelli F., Brivio F., Adrizzoia A., Tancini G., Conti A., Maestroni G.J. Neuroimmunotherapy of advanced solid neoplasm with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: Preliminary results. Eur. J. Cancer. 29:1993;185-189.
27. James S.P., Sack D.A., Rosenthal N.E., Mendelson W.B. Melatonin administration in insomnia. Neuropsychopharmacology. 3:1990;19-23.
28. Sarnel A., Wegmann A.M., Vejvoda M., Maass H., Gundel A., Schutz M. Influence of melatonin treatment on human circadian rhythimicity before and after a simulated 9 hour time shift. J. Biol. Rhythms. 6:1991;235-248.
29. Neri B., Fiorelli C., Moroni F., Nicita G., Paoletti M.C., Ponchietti R., Raugei A., Santoni G. A. Trippitelli and G. Grechi, Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study. Cancer. 73:1994;3015-3019.